Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.34 EUR
Change Today -0.03 / -2.19%
Volume 26.8K
EZBG On Other Exchanges
Symbol
Exchange
EN Brussels
As of 10:12 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

eckert-ziegler bebig (EZBG) Snapshot

Open
€1.38
Previous Close
€1.37
Day High
€1.38
Day Low
€1.30
52 Week High
04/28/14 - €2.06
52 Week Low
03/20/15 - €1.25
Market Cap
23.5M
Average Volume 10 Days
14.2K
EPS TTM
€-0.17
Shares Outstanding
17.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ECKERT-ZIEGLER BEBIG (EZBG)

Related News

No related news articles were found.

eckert-ziegler bebig (EZBG) Related Businessweek News

No Related Businessweek News Found

eckert-ziegler bebig (EZBG) Details

Eckert & Ziegler BEBIG s.a. develops, manufactures, and sells radiation equipment and related products and components based on isotope technology. The company offers IsoSeed, a seed implant for the treatment of prostate cancer; IsoCord, a seed chain with up to 70 seeds in a magazine that provides optimal radiation protection; IsoStrand, which consists of 10 IsoSeed spaced 1 cm apart; Permanent Seed Implant Dosimetry, a software for prostate brachytherapy; needles for LDR brachytherapy; and AnchorSeed, a loose seed with a bioabsorbable encapsulation. It also provides MultiSource, a HDR (high dose rate) afterloader system for the HDR brachytherapy applications; GyneSource, a five channel HDR afterloader developed for gynaecological brachytherapy treatments; HDR applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mould treatments; and HDRplus, a software that delivers HDR treatment plan. In addition, the company offers products for the temporary brachytherapy of eye cancers, including Ru-106 Eye Applicators, a brachytherapy source that is used in the treatment of uveal melanoma, retinoblastoma, and melanoma of the iris, as well as for other applications; I-125 Ophthalmic Seeds for use in COMS Eye Applicators to treat intraocular tumors, such as uveal melanoma or retinoblastoma; and Plaque Simulator, a software for 3D virtual simulation of ophthalmic plaque radiotherapy. Further, it provides radiotherapy accessories. The company offers its products to oncologists, radiologists, urologists, and medical physicists through a network of distributors and agents worldwide. The company was formerly known as International Brachytherapy s.a. and changed its name to Eckert & Ziegler BEBIG S.A. in June 2011. Eckert & Ziegler BEBIG s.a. was founded in 1996 and is headquartered in Seneffe, Belgium. Eckert & Ziegler BEBIG s.a. is a subsidiary of Eckert & Ziegler AG.

197 Employees
Last Reported Date: 03/27/15
Founded in 1996

eckert-ziegler bebig (EZBG) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: €281.4K
Managing Director, Director and Member of Man...
Total Annual Compensation: €163.1K
Compensation as of Fiscal Year 2013.

eckert-ziegler bebig (EZBG) Key Developments

Eckert & Ziegler BEBIG Announces Earnings Results for the Year 2014

Eckert & Ziegler BEBIG announced earnings results for the year 2014. For the year, the company reported sales of EUR 28.8 million compared to EUR 27.8 million in 2013. Loss per share was EUR 0.17.

Eckert & Ziegler BEBIG Provides Earnings Guidance for the Financial Year 2014

Eckert & Ziegler BEBIG provided earnings guidance for the financial year 2014. The company was not able to match the sales figures of the previous years in the last quarter of 2014. According to preliminary figures for the financial year 2014, management assumes that sales will be merely on par with the previous year's level of EUR 28 million. Instead of achieving earnings before interest and taxes (EBIT) comparable to EBIT levels in previous years, it will likely only be possible to realize a loss of almost EUR 3 million due to poorer capacity utilization in production.

Eckert & Ziegler BEBIG Announces Consolidated Earnings Results for the First Half of 2014

Eckert & Ziegler BEBIG announced consolidated earnings results for the first half of 2014. For the period, the company reported sales of EUR 13,903,000 against EUR 12,029,000 a year ago. Operating results was negative EUR 958,000 against positive of EUR 1,438,000 a year ago. Loss before interest and taxes was EUR 958,000 against profit before interest and taxes of EUR 1,438,000 a year ago. Loss before tax was EUR 1,251,000 against profit before tax of EUR 1,245,000 a year ago. Net loss was EUR 967,000 against net profit of EUR 658,000 a year ago. Net loss per standard and diluted share was EUR 0.06 against net profit per standard and diluted share of EUR 0.04 a year ago. Cash inflow used in operating activities was EUR 576,000 against EUR 96,000 a year ago. Additions of intangible non-current assets were EUR 605,000 against EUR 551,000 a year ago. Additions of tangible non-current assets were EUR 313,000 against EUR 203,000 a year ago. The increase in sales is exclusively a result of the recently acquired business in the U.S. Net debt increased slightly by EUR 1.5 million, totaling EUR 8.1 million at the reporting date compared to EUR 6.5 million as on December 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EZBG:BB €1.34 EUR -0.03

EZBG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $175.38 USD -0.87
Elekta AB kr81.25 SEK +0.80
View Industry Companies
 

Industry Analysis

EZBG

Industry Average

Valuation EZBG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT-ZIEGLER BEBIG, please visit www.bebig.eu/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.